The MFSA has issued a Circular introducing amendments to the Conduct of Business Rulebook (the “Rulebook”) applicable to insurance undertakings and intermediaries concerning the right to be forgotten for clients with a medical history of oncological diseases.
The amendments follow the enactment of the Protection against Adverse Consequences for Persons who Recovered from Oncological Diseases (Right to be Forgotten) Act (the “Right to be Forgotten Act”), which will come into force on 1 January 2027.
The MFSA has adopted a two-stage approach to the amendments, with the first set applying from 20 November 2026 until 31 December 2026, and the remaining amendments taking effect on 1 January 2027.
One of the main changes concerns the age threshold used to determine the period after which a client's previous oncological diagnosis can no longer be considered for insurance underwriting.
Under the original wording of Rule R.4.1.48A set to apply from 20 November 2026, personal data relating to a client's diagnosis of an oncological disease could not be used for the underwriting of an insurance policy related to a credit agreement after:
The Right to be Forgotten Act sets the age threshold at 25 years. The five-year period applies to persons diagnosed before reaching the age of 25, while the ten-year period applies to those diagnosed at 25 or older. The MFSA therefore amended Rule R.4.1.48A to reflect the new age threshold and to change how the client's age is assessed. Instead of referring to the client's age at the time of their last oncology treatment, the revised rule refers to their age on the date of diagnosis.
Under the revised rule, personal data relating to a client's diagnosis of an oncological disease may no longer be used for the underwriting of insurance policies related to credit agreements after:
The revised rule also clarifies the meaning of date of diagnosis, the date of the end of treatment, oncological disease and relapse. The date of diagnosis is the first day on which a qualified medical professional determines that a person has an oncological disease. The date of the end of treatment is determined by reference to the last active treatment in accordance with the applicable medical protocol. Relapse refers to the recurrence of the oncological disease following the end of treatment. Other health issues arising after treatment are not considered a relapse, even where they are a direct consequence of the oncological disease.
The MFSA has brought this amendment forward to give insurance undertakings and intermediaries time to update their systems ahead of the Act's commencement, rather than having to implement the revised age threshold within a short timeframe.
The revised Rule R.4.1.48A will apply from 20 November 2026 until 31 December 2026. During this period, its scope will remain limited to insurance policies issued to cover consumer loans, in line with the requirements of Directive (EU) 2023/225 (the Consumer Credit Directive II or “CCD II”).
Rules R.4.1.48B and R.4.1.48C will remain unchanged during this period. Rule R.4.1.48B requires regulated persons to give clients at least three days to compare insurance offers relating to consumer credit agreements, during which the offers must remain unchanged. Clients must be informed of this opportunity, although they may conclude an insurance policy before the three-day period expires if they expressly request to do so. Rule R.4.1.48C, in turn, identifies the relevant credit agreements by reference to Articles 2(2) and 3(3) of CCD II.
From 1 January 2027, Rules R.4.1.48A, R.4.1.48B and R.4.1.48C will be deleted and replaced by new Rules R.4.1.48D, R.4.1.48E and R.4.1.48F.
New Rule R.4.1.48D requires regulated persons issuing life insurance policies or any contracts or agreements ancillary thereto to comply with the Right to be Forgotten Act, as amended from time to time.
The new Rule R.4.1.48E also extends the scope of the existing three-day comparison period. From 1 January 2027, clients must be given at least three days to compare insurance offers relating to consumer credit agreements, credit agreements relating to residential immovable property and any contracts or agreements ancillary thereto. Clients must be informed of this opportunity. The offers must remain unchanged during this period, although clients may proceed earlier if they expressly request to do so.
This extension means that borrowers entering into mortgage credit agreements will also have the opportunity to compare insurance offers before committing to a policy. The MFSA intends this measure to strengthen consumer protection and bring the requirements under the consumer credit and mortgage credit frameworks into closer alignment.
Finally, new Rule R.4.1.48F clarifies the definitions applicable to the comparison requirement. Credit agreements will continue to have the meaning assigned to them under Articles 2(2) and 3(3) of CCD II, while credit agreements relating to residential immovable property will be defined by reference to the categories in Article 3(1)(a) and (b) of the Mortgage Credit Directive (Directive 2014/17/EU).
The Circular sets out two implementation dates which insurance undertakings and intermediaries should take into account when reviewing their existing procedures and systems.
From 20 November 2026, the revised Rule R.4.1.48A will require providers to apply the new age threshold and calculation periods when underwriting insurance policies covering consumer loans. Their underwriting procedures and systems should therefore reflect the new threshold of 25 years and use the client’s age at diagnosis, rather than at the last treatment, to determine the applicable period. The period itself runs from the end of treatment without relapse.
From 1 January 2027, providers will need to comply with the new Rules R.4.1.48D–F. This includes ensuring that procedures for issuing life insurance policies and ancillary agreements comply with the Right to be Forgotten Act and extending the three-day comparison period to insurance offers relating to residential immovable property credit agreements.
Insurance undertakings and intermediaries should ensure that the necessary changes are implemented by the relevant dates.
For further information on MFSA amendments or assistance in assessing the implications of these amendments for your business, please contact us at info@gtg.com.mt.
Authors: Dr Cherise Abela Grech and Dr Mattea Pullicino